Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors

NCT07625423 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Head & Neck Cancer
Nasopharyngeal Cancinoma (NPC)

Interventions

DRUG: EDS01 1.0×10^11 VP + Toripalimab
DRUG: EDS01 5.0×10^11 VP + Toripalimab
DRUG: EDS01 1.0×10^12 VP + Toripalimab

Sponsor

West China Hospital